Comment
. 2011 Jul;60(1):e1; author reply e2-3.
doi: 10.1016/j.eururo.2011.03.050.
Epub 2011 Apr 5.
Re: Willem Oosterlinck, Ziya Kirkali,Richard Sylvester, et al. Sequential intravesical chemoimmunotherapy with mitomycin C and bacillus Calmette-Guérin and with bacillus Calmette-Guérin alone in patients with carcinoma in situ of the urinary bladder: results of an EORTCGenito-urinary Group Randomized Phase 2 Trial (30993). Eur Urol 2011;59:438-46
- PMID: 21489685
- DOI: 10.1016/j.eururo.2011.03.050
Item in Clipboard
Comment
Re: Willem Oosterlinck, Ziya Kirkali,Richard Sylvester, et al. Sequential intravesical chemoimmunotherapy with mitomycin C and bacillus Calmette-Guérin and with bacillus Calmette-Guérin alone in patients with carcinoma in situ of the urinary bladder: results of an EORTCGenito-urinary Group Randomized Phase 2 Trial (30993). Eur Urol 2011;59:438-46
Eur Urol.
2011 Jul.
No abstract available
Comment on
-
Sequential intravesical chemoimmunotherapy with mitomycin C and bacillus Calmette-Guérin and with bacillus Calmette-Guérin alone in patients with carcinoma in situ of the urinary bladder: results of an EORTC genito-urinary group randomized phase 2 trial (30993).Eur Urol. 2011 Mar;59(3):438-46. doi: 10.1016/j.eururo.2010.11.038. Epub 2010 Dec 7. Eur Urol. 2011. PMID: 21156335 Clinical Trial.
Similar articles
-
Re: Per-Uno Malmström, Richard J. Sylvester, David E. Crawford, et al. An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guérin for non-muscle-invasive bladder cancer. Eur Urol 2009;56:247-56.Eur Urol. 2010 Feb;57(2):e7-9; author reply e10-1. doi: 10.1016/j.eururo.2009.10.033. Epub 2009 Nov 10. Eur Urol. 2010. PMID: 19914768 No abstract available.
-
Re: Per-Uno Malmström, Richard J. Sylvester, David E. Crawford, et al. An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guérin for non-muscle-invasive bladder cancer. Eur Urol 2009;56:247-56.Eur Urol. 2010 Aug;58(2):e23; author reply e24-5. doi: 10.1016/j.eururo.2010.05.032. Epub 2010 Jun 2. Eur Urol. 2010. PMID: 20542629 No abstract available.
-
Re: Richard J. Sylvester, Maurizio A. Brausi, Wim J. Kirkels, et al. Long-term efficacy results of EORTC genito-urinary group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-Guérin, and bacillus Calmette-Guérin plus isoniazid in patients with intermediate- and high-risk stage Ta T1 urothelial carcinoma of the bladder. Eur Urol 2010;57:766-73.Eur Urol. 2010 Jun;57(6):e57; author reply e58-9. doi: 10.1016/j.eururo.2010.02.037. Epub 2010 Mar 15. Eur Urol. 2010. PMID: 20227819 No abstract available.
-
Intravesical Bacillus Calmette-Guérin versus mitomycin C for Ta and T1 bladder cancer: Abridged summary of the Cochrane Review.Investig Clin Urol. 2020 Jul;61(4):349-354. doi: 10.4111/icu.2020.61.4.349. Epub 2020 Jun 29. Investig Clin Urol. 2020. PMID: 32665991 Free PMC article. Review. No abstract available.
-
[Management of Ta, T1, and in situ bladder carcinoma: what is new?].Prog Urol. 2008 May;18 Suppl 5:S94-8. doi: 10.1016/S1166-7087(08)72484-9. Prog Urol. 2008. PMID: 18585634 Review. French.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
